低钠血症鉴别诊断朱大龙ppt课件.ppt

《低钠血症鉴别诊断朱大龙ppt课件.ppt》由会员分享，可在线阅读，更多相关《低钠血症鉴别诊断朱大龙ppt课件.ppt（38页珍藏版）》请在三一办公上搜索。

1、低钠血症（ Hyponatremia ）,朱大龙南京大学医学院附属鼓楼医院,水、钠代谢的调节,定 义,血清钠135mmol/L为低钠血症； 仅反映钠在血浆中浓度的降低，并不一定表示体内总钠量的丢失，总体钠可以正常甚或稍有增加。临床上极为常见，特别在老年人中。主要症状为软弱乏力、恶心呕吐、头痛思睡、肌肉痛性痉挛、神经精神症状和可逆性共济失调等。,分类,根据渗透压低渗性低钠血症等渗型低钠血症高渗性低钠血症根据低钠血症发生时的血容量变化低血容量性低钠血症 失钠多于失水。 血容量正常性低钠血症 总体水增加而总钠不变。 高血容量的低钠血症 总体水增高大于血钠升高,根据血钠降低的程度可分为 重度低钠血症1

2、20mmol/L中度低钠血症130mmol/L轻度低钠血症135mmol/L 此外还有假性低钠血症，见于明显的高脂血症和高蛋白血症。,病 因,假性低钠血症（渗透压正常）高脂血症、高蛋白血症（显著升高）高渗透性性低钠血症（高血糖、甘露醇或甘油治疗）低血容量性低钠血症胃肠道消化液丢失（如呕吐、腹泻、胰腺炎及胰腺造瘘和胆瘘等； 皮肤水盐丢失（大量出汗、大面积三度烧伤、胰腺纤维性囊肿）体腔转移丢失 （小肠梗阻、腹膜炎、急性静脉阻塞、严重烧伤等）肾性失钠（慢性肾脏疾病、失盐性肾病、盐皮质功能减退、SIADH、糖尿病酮症酸中毒、利尿剂）脑性盐耗损综合征（下视丘脑或脑干损伤引起）,血容量正常性低钠血症SIA

3、DH糖皮质激素缺乏肾病综合症不适当利尿精神性多饮甲状腺功能减退症严重慢性肺部疾病、恶液质、营养不良高血容量性低钠血症充血性心力衰竭肝功能衰竭慢性肾功能衰竭肾病综合征,SIADH,恶性肿瘤（肺燕麦细胞癌、前列腺癌、胸腺癌、淋巴瘤等）肺部纵膈疾病- 肺炎、曲霉病、脓肿、TB, PPV中枢神经系统疾病 脓肿、创伤、脑膜炎、中风、SAH内分泌疾病 Addison病、甲减手术后急性间歇性卟啉症 药物性SSRI、苯丙胺相关药、长春新碱、环磷酰胺，卡马西平，溴隐亭NSAIDS：通过降低肾脏的前列腺素,低血容量性低钠血症（一）,低血容量性低钠血症（二）,正常容量或高容量性低钠血症（一）,正常容量或高容量性低钠

4、血症（二）,病理生理,低钠血症从病因来说，不外是钠的丢失和耗损，或者是总体水相对增多，总的效应是血浆渗透压降低(血钠浓度是血浆渗透压维系的主要成分)。失钠又常伴有失水，不管低钠血症的病因为何，有效血容量均缩减，从而引起非渗透压性ADH释放，以图增加肾小管对水的重吸收，以免血容量进一步缩减。然而这种保护机制更加重了血钠和血浆渗透压的降低，这种代偿机制发生于有效血容量缩减的早期，当血Na+下降到135mmol/L时，ADH释放则被抑制。,正常时细胞内渗透压保持稳态平衡。当血浆钠浓度降低，细胞外液渗透压下降，细胞外水流血细胞内，使细胞肿胀，以致细胞功能受损甚至破坏，其中以脑细胞肿胀，可导致低钠血症最

5、严重的临床表现。血容量缩减如果得不到纠正，则可使血压下降，肾血流量减少，肾小球滤过率降低，可导致肾前性氮质血症。,临床表现,低钠血症的临床表现严重程度取决于血钠水平和血钠下降的速率。血钠在125mmol/L以上时，极少引起症状；钠在125130mmol/L之间时，也只有胃肠道症状。此时主要症状为软弱乏力、恶心呕吐、头痛思睡、肌肉痛性痉挛、神经精神症状和可逆性共济失调等。,脑水肿临床表现有抽搐、木僵、昏迷和颅内压升高症状，严重可出现脑幕疝。如果低钠血症在48h内发生，则有很大危险，可导致永久性神经系统受损的后果。慢性低钠血症者，则有发生渗透性脱髓鞘的危险，特别在纠正低钠血症过分或过快时易于发生。

6、除脑细胞水肿和颅高压临床表现外，由于血容量缩减，可出现血压低、脉细速和循环衰竭，同时有失水的体征。总体钠正常的低钠血症则无脑水肿临床表现。,实验室检查,血生化及电解质测定血浆渗透压测定 尿渗透压测定 血BNP测定点尿钠浓度测定 血尿酸水平,渗透压,血浆渗透压（Posm)Posm = 2 (Na+K) +血糖+血尿素氮正常 = 2 (140) + 5 + 5 = 290 (275-290 mM) 尿渗透压（UOSM） :正常: 400-500 mM最大稀释 50-100 mM (USG 1.002-1.003)最大浓缩 900-1200 mM (USG 1.030-1.040)浓缩尿: 500

7、mM (至少!), USG 1.017UOSM POSM is not enough to R/O Diabetes Insipidus,诊 断,确定是否为真正的低钠血症血浆渗透压（Posm ）正常范围 280-295mOsm/kg如果 295 mOsm/kg高血糖或甘露醇的使用（高渗性低钠血症）如果在280-295 mOsm/kg之间 :假性低钠血症：高脂血症或高蛋白血症如果280 mOsm/kg评价容量状态,血浆渗透压 280 mOsm/kg高容量性:充血性心力衰竭、肝硬化、肾病综合症、急慢性肾功能衰竭正常容量性： SIADH、甲减、精神性多饮、肾病综合症不适当利尿、嗜啤酒狂、手术后、钠摄

8、入不足、极低蛋白饮食等低容量性胃肠消化液丢失、皮肤出汗、利尿剂使用、脑盐耗综合症、体腔转移丢失、盐皮质激素不足（Addison病）,低钠血症的诊断思路,低钠血症的治疗应根据病因、低钠血症的类型、低钠血症发生的急慢及伴随疾病而采取不同处理方法，故强调低钠血症的治疗应个别化，但总的治疗措施包括： 去除病因； 纠正低钠血症； 对症处理； 治疗合并症。,治 疗,低钠血症的纠正速度,24小时内升高10-12mmol/L，48小时内血钠升高18 mmol/L,治 疗,急性低钠血症 =脑水肿、脑疝方法:去除病因症状轻到中度:无需进一步干预治疗；严重症状:高渗盐水输注(3%) 3% NaCl检测输液速度-避免

9、中枢脑桥脱髓鞘病变检测血钠水平 q2h24小时内升高10-12mmol/L，48小时内血钠升高18 mmol/L,Verbalis, Joseph G., Stephen R. Goldsmith, Arthur Greenberg, Robert W. Schrier, and Richard H. Sterns. Hyponatremia Treatment Guidelines 2007: Expert Panel Recommendations. The American Journal of Medicine 120 (2007): S1-S21.,治 疗,慢性低钠血症 = 脑适应重

10、要是控制低钠血症的纠正速度 脑适应性、细胞内溶质外溢血钠纠正过快，大脑容易受损伤由于脑细胞不能重新摄取溶质，细胞萎缩“中枢脑桥髓鞘溶解” / “渗透性脱髓鞘作用” 大脑局限在颅内，构音困难、吞咽困难、癫痫、神智改变、四肢轻瘫、低血压1-3天内纠正低钠血症24小时内升高10-12mmol/L，48小时内血钠升高18 mmol/L,Hyponatremia Treatment Guidelines 2007: Expert Panel Recommendations. The American Journal of Medicine 120 (2007): S1-S21.,治 疗,慢性低钠血症 （

11、续）低血容量性: 生理盐水- 恢复组织灌注正常容量性和高容量性限制液体摄入 袢利尿剂/ 盐片口服 血管加压素受体拮抗剂-考尼伐坦、托伐普坦其他地美环素引起肾性尿崩症2-5天发生严重的多尿 高钠血症肾毒性、光敏感、皮疹尿素长期治疗有效 (5年)动物模型显示有益锂剂下调血管加压素刺激的水通道蛋白2的表达有效性不确定引起肾性尿崩症,hyponatremia Treatment Guidelines 2007: Expert Panel Recommendations. The American Journal of Medicine 120 (2007): S1-S21.,慢性低钠血症（等容量或高容

12、量性）,无症状:首选病因治疗限制水的摄入袢利尿剂/盐片摄入抑制ADH释放：地美环素V2 受体拮抗剂考尼伐坦、托伐普坦有症状:（低钠性脑病、严重脑水肿）3% 高渗盐水Desired change in Na TBWTBW: 0.6 weight (kg) in men & 0.5 weight (kg) in women缓慢纠正，避免并发症,抗利尿激素受体（AVPR）拮抗剂,一种新的治疗低钠血症的药物，阻断V2R与抗利尿激素受体结合，进而抑制腺苷酸环化酶信号途径从而排除自由水但是对尿钠、尿钾无作用。Conviptan已被美国FDA批准用于等容量和高容量性低钠血症患者的应用，而在2009年，欧洲E

13、MEA和美国FDA均批准Tolvaptan用于SIADH患者低钠血症的治疗。另外目前用于临床试验研究阶段的药物还包括Lixivaptan和Satavaptan。,Multi-center, double-blind, placebo controlled, randomly assigned (4days)Conivaptan 30min LD (20mg diluted to 100ml D5W) infusion 96hr CIV days 1-4 (diluted to 250ml)40mg/day80 mg/day Placebo 100ml D5W as LD 250 ml D5WI

14、mportant Exclusion Criteria:Hypovolemic hyponatremiaCardiac problems: Hyponatremia requiring immediate treatmentMedications interacting with CYP4503A4Other medications,Assessment of the Efficacy and Safety of Intravenous Conivaptan in Euvolemic and Hypervolemic Hyponatremia,American Journal of Nephr

15、ology 27 (2007): 447-57,Time to increase /= 4mEq/L :Conivaptan 40mg/day: 24 hoursConivaptan 80mg/day: 10 hoursPBO: no increase within 4 day infusionChange in serum Na from baseline to end of treatmentConivaptan 40mg/day: 6.3 mEq/LConivaptan 80mg/day: 9.4 mEq/LPBO: 0.8 mEq/LPatients with increase in

16、Na /=6mEq/L or Na /=135 mEq/LConivaptan 40mg/day: 69% (6.3)Conivaptan 80mg/day: 88.5% (23)PBO: 20.7% (6)Change in serum Na from Baseline to 6-9days post treatment :Conivaptan 40mg/day: 8.1mEq/L (n=13)Conivaptan 80mg/day: 4.7 mEq/L (n=26)PBO: 5.2 mEq/L (n=17),Assessment of the Efficacy and Safety of

17、Intravenous Conivaptan in Euvolemic and Hypervolemic Hyponatremia,Discontinuation was mainly due to Infusion site reactionsOther ADRs: hypotension, postural hypotension, pyrexia, hyperkalemia, infusion site thrombosis,Prospective, multi-center, randomized centrally, double-blind, placebo controlledC

18、onducted 2 trials to assess reproducibility (SALT-1 & SALT-2)Tolvaptan 15mg tab 1 tab PO Daily x 30 days OR PBOImportant Patient Population Criteria:InclusionEtiologies: CHF, cirrhosis or SIADHExclusion Criteria:Other etiologiesHypovolemic hyponatremiaOther cardiac diseases (post-MI, SVT, SBP90)Seru

19、m Na 120 mmol/L w/ neurological impairmentPoor prognosis not tolerating fluid shifts: short-term survival,Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia,New England Journal of Medicine 355 (2006): 2099-112,Similar Baseline Characteristics across study groups (except

20、 height in SALT-2), Mean baseline Na: 128 mEq/LCo-Administration/Co-intervention: Fluid restriction was not mandatory; treatment with other agents were not allowed (demeclocycline, lithium, urea)Dose adjustments were made at the discretion of the investigator at Day 4 Drug was administered until day

21、 30, final assessments done at day 37,Values were statistically significantIncreases in Na were greater in Tolvaptan group than PBO in both trials and in both stratifications at Day 4 and much more at Day 30Increases were more rapid (by day 4) and greater (marked hyponatremia),New England Journal of

22、 Medicine 355 (2006): 2099-112.,Tolvaptan patients reached normal Na levels on day 4 and 30 more than PBODay 4: SALT-1 (40% vs 13%) SALT-2 (55% vs11%) Day 30: SALT-1 (53% vs 25%) SALT-2 (58% vs25%) Less “marked” hyponatremia Day 4: SALT-1 (13% vs 49%) SALT-2 (10% vs 40%) Day 30: SALT-1 (7% vs 35%) S

23、ALT-2 (15% vs 32%) not sigSF-12 scoresShowed difference in “mental component summary” in “marked hyponatremia” patients, but not overallVitality, social functioning, calmness, sadnessNo difference in physical component summaryOTHER:Day 37 analysis: Na concentrations showed no difference between each

24、 arm,Tolvaptan (Samsca) Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia.,New England Journal of Medicine 355 (2006): 2099-112.,ADRMost common: Thirst (14%;5%); Dry mouth (13%;4%)Incidence: Tolvaptan: 171 patients PBO: 176, not all ADRs were deemed to be related to st

25、udy drugweakness, nausea, constipation, peripheral edema, ascites, diarrhea, fatigue, vomitingTolvaptan: 8 patients withdrew due to ADR Rash, dysguesia, nocturia, urinary frequency, exanthema, muscle weakness, hypernatremiaPBO: 8 patients withdrew due to ADR Rash, ARF, increased SCr, decreased Na, a

26、ggravated hyponatremia, vomitingCompleted Follow-up 7-days & 30-days:Tolvaptan: N=171 (76%)PBO: N=154 (69%)Study Withdrawal:Total: N= 123 Tolvaptan: 54 (24%)PBO: 69 (31%),Tolvaptan (Samsca) Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia.,Schrier, Robert G., Peter Gross, Mihai Gheorghiade, Tomas Berl, Joseph G. Verbalis, Frank Czerwiec, and Cesare Orlandi. Tolvaptan, a Selective Oral Vasopressin V2-Receptor Antagonist, for Hyponatremia. New England Journal of Medicine 355 (2006): 2099-112.,Conivaptan VS Tolvaptan,